Mechanisms of Weight Loss With SGLT2 Inhibition

NCT02360774 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes
Overweight
Obesity

Interventions

DRUG: Canagliflozin
DRUG: Placebo

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]